Lacosamide Upptrappningsförpackning (Endast För Ungdomar Och Barn Som Väger 50 Kg Eller Mer Samt Vux

Lacosamide, the active ingredient in Lacosamide Upptrappningsförpackning (Endast För Ungdomar Och Barn Som Väger 50 kg Eller Mer Samt Vux), is an anticonvulsant presented as an oral tablet for oral use. It is employed to treat partial‑onset seizures as adjunctive therapy in adolescents, children weighing at least 50 kg, and adults.

GNH USA supplies Lacosamide Upptrappningsförpackning as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across global markets, through a robust supply chain network.

Lacosamide is used in the treatment of seizure disorders that originate in a specific brain region.

Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic therapy. Adjunctive therapy for epilepsy: improves overall seizure control in patients not adequately controlled by other drugs. Focal epilepsy in adolescents and adults: provides an additional option for patients weighing ≥50 kg.

Lacosamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue

Serious or Rare Side Effects: - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior

When prescribing lacosamide, clinicians should consider several precautionary measures to ensure safe use.

Dose titration: increase gradually according to prescriber guidance. Renal impairment: evaluate renal function and adjust dose if necessary. Hepatic impairment: monitor liver enzymes and consider dose modification. Cardiac history: obtain baseline ECG and monitor for PR‑interval changes. Pregnancy: use only if potential benefit justifies potential risk to the fetus. Store at room temperature: keep in original container, protect from moisture.

Lacosamide can interact with other medicines, influencing its plasma concentration or enhancing pharmacodynamic effects.

Major Interactions (Avoid): - Carbamazepine: may reduce lacosamide plasma levels. - Phenytoin: may reduce lacosamide plasma levels. - Strong CYP2C19 inhibitors (e.g., fluconazole): may increase lacosamide exposure.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Alcohol: may increase dizziness and drowsiness. - Other antiepileptics (e.g., valproate): monitor efficacy and tolerability.